Rock Springs Capital Management
Latest statistics and disclosures from Rock Springs Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HUM, IMCR, AGL, NBIX, BPMC, and represent 21.06% of Rock Springs Capital Management's stock portfolio.
- Added to shares of these 10 stocks: BSX (+$47M), PEN (+$33M), BPMC (+$25M), IMVT (+$25M), AMGN (+$18M), ABOS (+$12M), IMGN (+$10M), INSP (+$8.8M), PHR (+$8.8M), DXCM (+$8.7M).
- Started 7 new stock positions in CRVO, IMVT, AMGN, ABOS, SGMT, INSP, SYRE.
- Reduced shares in these 10 stocks: ARGX (-$45M), PODD (-$29M), CNMD (-$28M), Horizon Therapeutics (-$28M), Abcam Plc Ads (-$26M), HUM (-$16M), Chinook Therapeutics (-$15M), ALNY (-$12M), BHVN (-$9.6M), CYTK (-$9.2M).
- Sold out of its positions in Aeglea Biotherapeutics, ALT, ANAB, BDTX, Chinook Therapeutics, CNMD, GH, Paratek Pharmaceuticals, BHVN, NVCR.
- Rock Springs Capital Management was a net seller of stock by $-34M.
- Rock Springs Capital Management has $3.7B in assets under management (AUM), dropping by -11.18%.
- Central Index Key (CIK): 0001595725
Tip: Access up to 7 years of quarterly data
Positions held by Rock Springs Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Rock Springs Capital Management
Rock Springs Capital Management holds 120 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Humana (HUM) | 5.7 | $212M | -7% | 437k | 486.52 |
|
Immunocore Hldgs Ads (IMCR) | 4.1 | $153M | -2% | 2.9M | 51.90 |
|
Agilon Health (AGL) | 3.9 | $147M | 8.3M | 17.76 |
|
|
Neurocrine Biosciences (NBIX) | 3.7 | $139M | -3% | 1.2M | 112.50 |
|
Blueprint Medicines (BPMC) | 3.6 | $135M | +22% | 2.7M | 50.22 |
|
Argenx Se Sponsored Adr (ARGX) | 3.4 | $127M | -26% | 259k | 491.63 |
|
Penumbra (PEN) | 3.3 | $122M | +37% | 504k | 241.91 |
|
UnitedHealth (UNH) | 3.1 | $116M | 230k | 504.19 |
|
|
Evolent Health Cl A (EVH) | 2.8 | $105M | 3.9M | 27.23 |
|
|
Intuitive Surgical Com New (ISRG) | 2.3 | $87M | 299k | 292.29 |
|
|
Karuna Therapeutics Ord (KRTX) | 2.3 | $86M | +2% | 505k | 169.09 |
|
IDEXX Laboratories (IDXX) | 2.3 | $85M | 195k | 437.27 |
|
|
Seagen | 2.3 | $85M | 400k | 212.15 |
|
|
West Pharmaceutical Services (WST) | 2.0 | $76M | 202k | 375.21 |
|
|
Akero Therapeutics (AKRO) | 1.9 | $72M | -8% | 1.4M | 50.58 |
|
EXACT Sciences Corporation (EXAS) | 1.9 | $70M | +7% | 1.0M | 68.22 |
|
Agios Pharmaceuticals (AGIO) | 1.8 | $67M | 2.7M | 24.75 |
|
|
Align Technology (ALGN) | 1.8 | $66M | 217k | 305.32 |
|
|
Acadia Healthcare (ACHC) | 1.7 | $64M | 908k | 70.31 |
|
|
Boston Scientific Corporation (BSX) | 1.6 | $61M | +333% | 1.2M | 52.80 |
|
Insulet Corporation (PODD) | 1.6 | $61M | -32% | 380k | 159.49 |
|
Mirum Pharmaceuticals (MIRM) | 1.5 | $58M | 1.8M | 31.60 |
|
|
Cerevel Therapeutics Hldng I (CERE) | 1.5 | $55M | 2.5M | 21.83 |
|
|
Dex (DXCM) | 1.5 | $55M | +19% | 584k | 93.30 |
|
Ultragenyx Pharmaceutical (RARE) | 1.4 | $53M | +6% | 1.5M | 35.65 |
|
Alnylam Pharmaceuticals (ALNY) | 1.3 | $50M | -18% | 280k | 177.10 |
|
Mirati Therapeutics (MRTX) | 1.3 | $49M | 1.1M | 43.56 |
|
|
Sarepta Therapeutics (SRPT) | 1.3 | $48M | -7% | 392k | 121.22 |
|
Edwards Lifesciences (EW) | 1.2 | $45M | 647k | 69.28 |
|
|
Freshpet (FRPT) | 1.2 | $44M | 663k | 65.88 |
|
|
Xenon Pharmaceuticals (XENE) | 1.1 | $40M | 1.2M | 34.16 |
|
|
Ascendis Pharma A/s Sponsored Adr (ASND) | 1.1 | $40M | 426k | 93.64 |
|
|
Rhythm Pharmaceuticals (RYTM) | 1.0 | $37M | 1.6M | 22.93 |
|
|
Phreesia (PHR) | 0.9 | $33M | +36% | 1.8M | 18.68 |
|
Irhythm Technologies (IRTC) | 0.9 | $33M | +13% | 351k | 94.26 |
|
Pacira Pharmaceuticals (PCRX) | 0.9 | $32M | 1.1M | 30.68 |
|
|
Accolade (ACCD) | 0.8 | $31M | +3% | 2.9M | 10.58 |
|
Legend Biotech Corp Sponsored Ads (LEGN) | 0.8 | $31M | 458k | 67.17 |
|
|
Zai Lab Adr (ZLAB) | 0.8 | $30M | 1.2M | 24.31 |
|
|
Prothena Corp SHS (PRTA) | 0.8 | $30M | -18% | 614k | 48.25 |
|
Horizon Therapeutics Pub L SHS | 0.8 | $30M | -48% | 256k | 115.69 |
|
Shockwave Med (SWAV) | 0.8 | $29M | +28% | 148k | 199.10 |
|
Abcam Ads | 0.8 | $29M | -46% | 1.3M | 22.63 |
|
Madrigal Pharmaceuticals (MDGL) | 0.8 | $29M | 196k | 146.04 |
|
|
Amylyx Pharmaceuticals (AMLX) | 0.8 | $28M | 1.5M | 18.31 |
|
|
Aclaris Therapeutics (ACRS) | 0.7 | $27M | 4.0M | 6.85 |
|
|
Dynavax Technologies Corp Com New (DVAX) | 0.7 | $27M | 1.8M | 14.77 |
|
|
Select Sector Spdr Tr Sbi Healthcare (XLV) | 0.7 | $26M | 200k | 128.74 |
|
|
Lifestance Health Group (LFST) | 0.7 | $25M | +26% | 3.7M | 6.87 |
|
Immunovant (IMVT) | 0.7 | $25M | NEW | 644k | 38.39 |
|
Olink Hldg Ab Sponsored Ads (OLK) | 0.7 | $25M | 1.7M | 14.75 |
|
|
Brooks Automation (AZTA) | 0.6 | $24M | 478k | 50.19 |
|
|
BioMarin Pharmaceutical (BMRN) | 0.6 | $23M | 265k | 88.48 |
|
|
Nevro (NVRO) | 0.6 | $23M | 1.2M | 19.22 |
|
|
Immatics SHS (IMTX) | 0.6 | $22M | -26% | 1.9M | 11.58 |
|
Kymera Therapeutics (KYMR) | 0.6 | $21M | 1.5M | 13.90 |
|
|
Warby Parker Cl A Com (WRBY) | 0.6 | $21M | +18% | 1.6M | 13.16 |
|
Revolution Medicines (RVMD) | 0.5 | $20M | +3% | 725k | 27.68 |
|
Merus N V (MRUS) | 0.5 | $20M | +75% | 838k | 23.58 |
|
Amgen (AMGN) | 0.5 | $18M | NEW | 68k | 268.76 |
|
BioCryst Pharmaceuticals (BCRX) | 0.5 | $18M | +2% | 2.6M | 7.08 |
|
Disc Medicine (IRON) | 0.5 | $17M | 364k | 46.98 |
|
|
Travere Therapeutics (TVTX) | 0.4 | $16M | +18% | 1.8M | 8.94 |
|
Inozyme Pharma (INZY) | 0.4 | $16M | +7% | 3.7M | 4.20 |
|
Celldex Therapeutics Com New (CLDX) | 0.4 | $14M | +18% | 500k | 27.52 |
|
Amicus Therapeutics (FOLD) | 0.3 | $13M | 1.1M | 12.16 |
|
|
Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.3 | $13M | -13% | 562k | 22.35 |
|
ImmunoGen (IMGN) | 0.3 | $12M | +574% | 759k | 15.87 |
|
Acumen Pharmaceuticals (ABOS) | 0.3 | $12M | NEW | 2.8M | 4.15 |
|
Mineralys Therapeutics (MLYS) | 0.3 | $11M | 1.2M | 9.51 |
|
|
Compass Therapeutics (CMPX) | 0.3 | $11M | 5.5M | 1.97 |
|
|
Krystal Biotech (KRYS) | 0.3 | $11M | +159% | 91k | 116.00 |
|
Mereo Biopharma Group Spon Ads (MREO) | 0.3 | $9.9M | +9% | 7.7M | 1.29 |
|
Edap Tms S A Sponsored Adr (EDAP) | 0.3 | $9.5M | +14% | 1.4M | 7.02 |
|
Inspire Med Sys (INSP) | 0.2 | $8.8M | NEW | 45k | 198.44 |
|
Reneo Pharmaceuticals (RPHM) | 0.2 | $8.7M | 1.1M | 7.62 |
|
|
Pliant Therapeutics (PLRX) | 0.2 | $8.5M | 491k | 17.34 |
|
|
Pulmonx Corp (LUNG) | 0.2 | $6.7M | 652k | 10.33 |
|
|
Icosavax (ICVX) | 0.2 | $6.7M | 868k | 7.75 |
|
|
Sagimet Biosciences Com Ser A (SGMT) | 0.2 | $6.5M | NEW | 738k | 8.80 |
|
Aura Biosciences (AURA) | 0.2 | $6.5M | -29% | 723k | 8.97 |
|
Spruce Biosciences (SPRB) | 0.2 | $6.2M | 2.7M | 2.26 |
|
|
Relay Therapeutics (RLAY) | 0.2 | $5.7M | 674k | 8.41 |
|
|
Macrogenics (MGNX) | 0.1 | $5.5M | +4% | 1.2M | 4.66 |
|
Novavax Com New (NVAX) | 0.1 | $4.7M | +20% | 648k | 7.24 |
|
Mersana Therapeutics (MRSN) | 0.1 | $4.3M | 3.4M | 1.27 |
|
|
Cytokinetics Com New (CYTK) | 0.1 | $4.0M | -70% | 134k | 29.46 |
|
Aurinia Pharmaceuticals (AUPH) | 0.1 | $3.7M | 480k | 7.77 |
|
|
Gossamer Bio Note 5.000% 6/0 (Principal) | 0.1 | $3.7M | 9.6M | 0.39 |
|
|
Fulcrum Therapeutics (FULC) | 0.1 | $3.2M | 728k | 4.44 |
|
|
Health Catalyst (HCAT) | 0.1 | $3.1M | -66% | 308k | 10.12 |
|
Xilio Therapeutics (XLO) | 0.1 | $3.0M | 1.4M | 2.11 |
|
|
Gossamer Bio (GOSS) | 0.1 | $2.7M | +196% | 3.3M | 0.83 |
|
Beam Therapeutics (BEAM) | 0.1 | $2.7M | 111k | 24.05 |
|
|
Travere Therapeutics Note 2.500% 9/1 (Principal) | 0.1 | $2.7M | 3.3M | 0.82 |
|
|
Vigil Neuroscience (VIGL) | 0.1 | $2.5M | 472k | 5.39 |
|
|
Biomea Fusion (BMEA) | 0.1 | $2.5M | -78% | 181k | 13.76 |
|
Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $2.2M | 2.8M | 0.78 |
|
|
Essa Pharma Com New (EPIX) | 0.1 | $2.1M | +2% | 677k | 3.09 |
|
Applied Therapeutics (APLT) | 0.1 | $2.0M | +3% | 809k | 2.49 |
|
Aeglea Biotherapeutics Com New (SYRE) | 0.0 | $1.7M | NEW | 137k | 12.25 |
|
Neurocrine Biosciences Note 2.250% 5/1 (Principal) | 0.0 | $1.5M | 1.0M | 1.50 |
|
|
Leap Therapeutics Com New (LPTX) | 0.0 | $1.5M | 1.1M | 1.38 |
|
|
Acelyrin (SLRN) | 0.0 | $1.4M | 142k | 10.17 |
|
|
Fate Therapeutics (FATE) | 0.0 | $1.3M | 612k | 2.12 |
|
|
Compugen Ord (CGEN) | 0.0 | $1.2M | 1.3M | 0.93 |
|
|
Theseus Pharmaceuticals (THRX) | 0.0 | $1.2M | 437k | 2.69 |
|
|
Design Therapeutics (DSGN) | 0.0 | $1.1M | 460k | 2.36 |
|
|
Vincerx Pharma Com New (VINC) | 0.0 | $901k | 892k | 1.01 |
|
|
Kinnate Biopharma (KNTE) | 0.0 | $568k | -45% | 406k | 1.40 |
|
Nevro Corp Note 2.750% 4/0 (Principal) | 0.0 | $472k | 500k | 0.94 |
|
|
Nkarta (NKTX) | 0.0 | $461k | 332k | 1.39 |
|
|
Cervomed (CRVO) | 0.0 | $370k | NEW | 80k | 4.62 |
|
Invitae (NVTA) | 0.0 | $354k | -64% | 586k | 0.61 |
|
Acelrx Pharmaceuticals Com New (ACRX) | 0.0 | $184k | 317k | 0.58 |
|
|
Tempest Therapeutics (TPST) | 0.0 | $163k | 536k | 0.30 |
|
|
Atreca Cl A Com (BCEL) | 0.0 | $95k | 363k | 0.26 |
|
|
Spero Therapeutics (SPRO) | 0.0 | $69k | -91% | 57k | 1.21 |
|
Gamida Cell SHS (GMDA) | 0.0 | $54k | -92% | 52k | 1.03 |
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $13k | 134k | 0.10 |
|
Past Filings by Rock Springs Capital Management
SEC 13F filings are viewable for Rock Springs Capital Management going back to 2013
- Rock Springs Capital Management 2023 Q3 filed Nov. 14, 2023
- Rock Springs Capital Management 2023 Q2 filed Aug. 14, 2023
- Rock Springs Capital Management 2023 Q1 filed May 15, 2023
- Rock Springs Capital Management 2022 Q4 filed Feb. 14, 2023
- Rock Springs Capital Management 2022 Q3 filed Nov. 14, 2022
- Rock Springs Capital Management 2022 Q2 filed Aug. 15, 2022
- Rock Springs Capital Management 2022 Q1 filed May 16, 2022
- Rock Springs Capital Management 2021 Q4 filed Feb. 14, 2022
- Rock Springs Capital Management 2021 Q3 filed Nov. 15, 2021
- Rock Springs Capital Management 2021 Q2 filed Aug. 16, 2021
- Rock Springs Capital Management 2021 Q1 filed May 17, 2021
- Rock Springs Capital Management 2020 Q4 filed Feb. 16, 2021
- Rock Springs Capital Management 2020 Q3 filed Nov. 16, 2020
- Rock Springs Capital Management 2020 Q2 filed Aug. 14, 2020
- Rock Springs Capital Management 2020 Q1 filed May 15, 2020
- Rock Springs Capital Management 2019 Q4 filed Feb. 14, 2020